Search Within

Roni Shouval

  1. "GME, Medicine"
Formats
  1. Meeting Abstract (38)
  2. Journal Article (21)
  3. Review (2)
  4. Editorial (1)
  5. Research Letter (1)
Groups
  1. GME, Medicine (63)
  2. Graduate Medical Education (63)
  3. Hematologic Malignancies, Division of (63)
  4. Hematology-Oncology Fellows (61)
  5. Center for Hematologic Malignancies (59)
  6. Department of Medicine (59)

More Groups

People
  1. Miguel-Angel Perales (54)
  2. Gunjan Shah (52)
  3. Michael Scordo (50)
  4. Maria Palomba (49)
  5. Gilles Salles (46)
  6. Richard Lin (38)

More People

Years
  1. 2025 (15)
  2. 2024 (22)
  3. 2023 (19)
  4. 2022 (6)
  5. 2021 (1)
Publications
  1. Blood (31)
  2. Bone Marrow Transplantation (5)
  3. Transplantation and Cellular Therapy (3)
  4. Blood Advances (2)
  5. Blood Cancer Journal (2)
  6. British Journal of Haematology (2)

More Publications

Publishers
  1. American Society of Hematology (33)
  2. Nature Publishing Group (11)
  3. Elsevier Inc. (5)
  4. American Association for Cancer Research (3)
  5. John Wiley & Sons (2)
  6. Wiley Blackwell (2)

More Publishers

Results (63)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The impact of cardiovascular vulnerabilities in non Hodgkin lymphoma patients treated with chimeric antigen receptor T cell therapy
    Meeting Abstract

    Landego, I.; Flynn, J. R.; Goldman, A.; Devlin, S. M.; Luttwak, E.; Luna De Abia, A.; Corona, M.; Kedmi, M.; Sdayoor, I.; Fried, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Detection of CAR-T cell persistence with digital droplet PCR: Correlation of in vivo expansion with clinical outcomes in a cohort of B-cell lymphoma patients
    Meeting Abstract

    Cassanello, G.; Borsu, L.; Arcila, M. E.; Yao, J.; Boroujeni, A. M.; Ewalt, M.; Patel, U.; Chan, R.; Gray, B.; Luna De Abia, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of response to systemic bridging therapy on clinical outcomes and cytokine profiles in patients receiving CD19-CAR T-cell therapy for B-cell lymphoma
    Meeting Abstract

    Wills, B.; Shouval, R.; Flynn, J. R.; Devlin, S. M.; Parascondola, A.; Saldia, A.; Imber, B. S.; Tomas, A. A.; Landego, I.; Lin, R. J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluation of the impact of tocilizumab use in recipients of CAR T cells for non-Hodgkin lymphoma
    Meeting Abstract

    Cassanello, G.; Luttwak, E.; Devlin, S. M.; Luna De Abia, A.; Corona, M.; Landego, I.; Parascondola, A.; Saldia, A.; Tomas, A. A.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Higher CD4+T cell counts after CAR-T in large B-cell lymphomas are significantly associated with better overall survival
    Meeting Abstract

    Luan, D.; Shouval, R.; Fei, T.; Luttwak, E.; Luna, A.; Corona, M.; Palomba, M. L.; Parascondola, A.; Scordo, M.; Shah, G. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • An inflammatory biomarker signature reproducibly predicts CAR-T treatment failure in patients with aggressive lymphoma across the ZUMA trials cohorts
    Meeting Abstract

    Raj, S.; Xie, J.; Fei, T.; Song, Q.; Kim, J. J.; To, C.; van den Brink, M. R. M.; Perales, M. A.; Mattie, M.; Shouval, R.
    Blood (2023)

    Fulltext@MSK | Save
  • A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2
    Meeting Abstract

    Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome
    Meeting Abstract

    Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J. R.; Devlin, S. M.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Wills, B.; Tomas, A. A.; more...
    Blood (2023)

    Fulltext@MSK | Save